Page 5 of 6
During the study, one patient (less than 1%) had a serious side effect of inflammation in
the sinuses.
The table below shows the number of patients (percent) with non-serious side effects
reported by 3% or more of patients during the study.
Number of patients (percent) with non-serious side effects reported
by 3% or more of patients
Mepolizumab
102 patients
Injection site reaction 4 (4%)
Headache 3 (3%)
How has this study helped patients and researchers?
The main objective of this study was to assess the long-term safety of mepolizumab in
patients with HES who completed Study 200622. Eight patients had serious adverse
events during the on-treatment period. No patients had anti-mepolizumab antibodies
after Day 1.
Are there plans for further studies?
Other studies of mepolizumab in patients with HES have been conducted. No new
studies are planned at this time.
Where can I find more information about this study?
Clinical studies have unique study numbers that are included in publications and other
information about the study. The unique study numbers associated with this study are
shown below with internet links to scientific summaries.
The scientific summaries include more details about the requirements for study
enrolment, the study visit schedule, results from other endpoints, and more detailed
information about adverse events.